Published: 24 September 2022
Author(s): David G. Gent, José M. Rivera-Caravaca, Rebecca Dobson, David J. Wright, Gregory Y.H. Lip, Liverpool Centre for Cardiovascular Science
Section: Letter to the Editor

Ibrutinib, an irreversible inhibitor of Bruton's Tyrosine Kinase (BTK), forms the standard of care for certain B cell malignancies including chronic lymphocytic leukaemia (CLL). Atrial fibrillation (AF) affects up to 16% of patients who commence ibrutinib and is associated with a worse prognosis and shorter overall survival time [1,2]. Similarly, ibrutinib treatment has been associated with incident hypertension and other arrhythmias such as high-grade heart block, ventricular tachycardia, and ventricular fibrillation [3–5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.